83 related articles for article (PubMed ID: 22555104)
1. Ovarian low-grade serous carcinoma: a comprehensive update.
Diaz-Padilla I; Malpica AL; Minig L; Chiva LM; Gershenson DM; Gonzalez-Martin A
Gynecol Oncol; 2012 Aug; 126(2):279-85. PubMed ID: 22555104
[TBL] [Abstract][Full Text] [Related]
2. High-grade serous ovarian cancer: the clone wars.
Salomon-Perzyński A; Salomon-Perzyńska M; Michalski B; Skrzypulec-Plinta V
Arch Gynecol Obstet; 2017 Mar; 295(3):569-576. PubMed ID: 28154920
[TBL] [Abstract][Full Text] [Related]
3. Current concept of low-grade serous ovarian carcinoma.
Nakayama K; Razia S; Ishibashi T; Kyo S
Transl Cancer Res; 2024 Jan; 13(1):6-10. PubMed ID: 38410232
[No Abstract] [Full Text] [Related]
4. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors.
Burks RT; Sherman ME; Kurman RJ
Am J Surg Pathol; 1996 Nov; 20(11):1319-30. PubMed ID: 8898836
[TBL] [Abstract][Full Text] [Related]
5. Integrated genomic characterization of endometrial carcinoma.
; Kandoth C; Schultz N; Cherniack AD; Akbani R; Liu Y; Shen H; Robertson AG; Pashtan I; Shen R; Benz CC; Yau C; Laird PW; Ding L; Zhang W; Mills GB; Kucherlapati R; Mardis ER; Levine DA
Nature; 2013 May; 497(7447):67-73. PubMed ID: 23636398
[TBL] [Abstract][Full Text] [Related]
6. Low-grade serous ovarian cancer: A review.
Kaldawy A; Segev Y; Lavie O; Auslender R; Sopik V; Narod SA
Gynecol Oncol; 2016 Nov; 143(2):433-438. PubMed ID: 27581327
[TBL] [Abstract][Full Text] [Related]
7. Low-grade serous ovarian cancer: State of the science.
Slomovitz B; Gourley C; Carey MS; Malpica A; Shih IM; Huntsman D; Fader AN; Grisham RN; Schlumbrecht M; Sun CC; Ludemann J; Cooney GA; Coleman R; Sood AK; Mahdi H; Wong KK; Covens A; O'Malley DM; Lecuru F; Cobb LP; Caputo TA; May T; Huang M; Siemon J; Fernández ML; Ray-Coquard I; Gershenson DM
Gynecol Oncol; 2020 Mar; 156(3):715-725. PubMed ID: 31969252
[TBL] [Abstract][Full Text] [Related]
8. A Comprehensive Review of Ovarian Serous Carcinoma.
Hatano Y; Hatano K; Tamada M; Morishige KI; Tomita H; Yanai H; Hara A
Adv Anat Pathol; 2019 Sep; 26(5):329-339. PubMed ID: 31368906
[TBL] [Abstract][Full Text] [Related]
9. Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions.
Grisham RN; Iyer G
Curr Treat Options Oncol; 2018 Sep; 19(11):54. PubMed ID: 30225651
[TBL] [Abstract][Full Text] [Related]
10. DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas.
Bildik G; Gray JP; Mao W; Yang H; Ozyurt R; Orellana VR; De Wever O; Carey MS; Bast RC; Lu Z
Autophagy; 2024 Mar; 20(3):675-691. PubMed ID: 38169324
[TBL] [Abstract][Full Text] [Related]
11. Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma.
Hollis RL; Thomson JP; van Baal J; Ilenkovan N; Churchman M; van de Vijver K; Dijk F; Meynert AM; Bartos C; Rye T; Croy I; Diana P; van Gent M; Creedon H; Nirsimloo R; Lok C; Gourley C; Herrington CS
Sci Rep; 2023 May; 13(1):7681. PubMed ID: 37169775
[TBL] [Abstract][Full Text] [Related]
12. The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer.
Wallis B; Bowman KR; Lu P; Lim CS
Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671544
[TBL] [Abstract][Full Text] [Related]
13. Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
Gasimli K; Raab M; Tahmasbi Rad M; Kurunci-Csacsko E; Becker S; Strebhardt K; Sanhaji M
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142803
[TBL] [Abstract][Full Text] [Related]
14. Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.
Shanta K; Nakayama K; Hossain MM; Razia S; Ishibashi T; Ishikawa M; Yamashita H; Kanno K; Sato S; Nakayama S; Otsuki Y; Kyo S
Curr Oncol; 2022 Jun; 29(6):4020-4033. PubMed ID: 35735430
[TBL] [Abstract][Full Text] [Related]
15. High expression level of miR-1260 family in the peripheral blood of patients with ovarian carcinoma.
Ghafour AA; Odemis DA; Tuncer SB; Kurt B; Saral MA; Erciyas SK; Erdogan OS; Celik B; Saip P; Yazici H
J Ovarian Res; 2021 Oct; 14(1):131. PubMed ID: 34629107
[TBL] [Abstract][Full Text] [Related]
16. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan.
Kang JH; Lai YL; Cheng WF; Kim HS; Kuo KT; Chen YL; Lee YY
Sci Rep; 2020 Nov; 10(1):20012. PubMed ID: 33203969
[TBL] [Abstract][Full Text] [Related]
17. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ; Grisham RN; Banerjee S; Kalbacher E; Mirza MR; Romero I; Vuylsteke P; Coleman RL; Hilpert F; Oza AM; Westermann A; Oehler MK; Pignata S; Aghajanian C; Colombo N; Drill E; Cibula D; Moore KN; Christy-Bittel J; Del Campo JM; Berger R; Marth C; Sehouli J; O'Malley DM; Churruca C; Boyd AP; Kristensen G; Clamp A; Ray-Coquard I; Vergote I
J Clin Oncol; 2020 Nov; 38(32):3753-3762. PubMed ID: 32822286
[TBL] [Abstract][Full Text] [Related]
18. Response to trametinib in recurrent low-grade serous ovarian cancer with
Champer M; Miller D; Kuo DY
Gynecol Oncol Rep; 2019 May; 28():26-28. PubMed ID: 30809568
[TBL] [Abstract][Full Text] [Related]
19. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer.
Gao Q; Yang Z; Xu S; Li X; Yang X; Jin P; Liu Y; Zhou X; Zhang T; Gong C; Wei X; Liu D; Sun C; Chen G; Hu J; Meng L; Zhou J; Sawada K; Fruscio R; Grunt TW; Wischhusen J; Vargas-Hernández VM; Pothuri B; Coleman RL
J Exp Med; 2019 Mar; 216(3):688-703. PubMed ID: 30710055
[TBL] [Abstract][Full Text] [Related]
20. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
